ShiraTronics Initiates IDE Pivotal Study of Implantable Neuromodulation Therapy for Chronic Migraine
- Written by PR Newswire
![]() |
First Implants of Innovative Device Completed in the United States and Australia
MINNEAPOLIS, Dec. 3, 2024 /PRNewswire/ -- ShiraTronics, a clinical-stage innovator in neuromodulation technology, today announced the initiation of its U.S. Food and Drug Administration (FDA)-approved Investigation Device Exemption (IDE) pivotal trial, the...















